Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

María Vieito; Víctor Moreno; Anna Spreafico; Irene Braña; Judy S. Wang; Meir Preis; Tatiana Hernández‐Guerrero; Sofia Genta; Aaron R. Hansen; Bernard Doger; Vladimir Galvao; Laurie Lenox; Regina J. Brown; Anna Kalota; Jaydeep Mehta; Friederike Pastore; Bharvin Patel; Pankaj Mistry; Junchen Gu; Josh Lauring; Manish R. Patel

doi:10.1158/1078-0432.27033220

Abstract

Supplementary Figure 1: Overall Response Over Time on JNJ-64619178 Treatment A. Dose Cohorts 0.5 mg - 1.5 mg (schedule A&B). B. Dose Cohorts 2.0 mg - 4.0 mg (schedule A&B)

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vieito et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db64358752275d https://doi.org/10.1158/1078-0432.27033220

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

Abstract

Discussion

Cite This Study

Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers